Levels of adiponectin,C-reactive protein and interleukin-1 receptor antagonist are associated with the relative change in body mass index between childhood and adulthood
Free accessResearch articleFirst published online December, 2007
Levels of adiponectin,C-reactive protein and interleukin-1 receptor antagonist are associated with the relative change in body mass index between childhood and adulthood
Obesity has been related to subclinical inflammation and decreased levels of adiponectin. We examined the relationship between inflammatory markers and adiponectin and the change in body mass index (BMI) between childhood and adulthood. Our study included 368 subjects (176 men and 192 women) from a population-based cohort whose weight and height had been recorded at the age of seven years. They participated in this study as adults (with a mean age of 46 years); levels of adiponectin, interleukin-1 receptor antagonist (IL-1 Ra) and high-sensitivity C-reactive protein (hs-CRP) were measured. The relative change of BMI from childhood to adulthood was significantly associated with levels of IL-1 Ra (men: r=0.27 [95% CI: 0.12 to 0.40] and women: 0.64 [0.55 to 0.72]), hs-CRP (r=0.15 and 0.52, respectively) and adiponectin (r=−0.13 and −0.29, respectively) in both genders.
Decreased levels of adiponectin and elevated levels of IL-1 Ra and hs-CRP at adulthood appear to be related to the change in BMI between childhood and adulthood.
1. Reaven GM.Banting Lecture 1988: role of insulin resistance in human diabetes. Diabetes1988;37:1595–607.
2.
2. Trayhurn PBeattie HJ.Physiological role of adipose tissue: white adipose tissue as endocrine and secretory organ. Proc Nutr Soc2001;60:329–39.
3.
3. Weyer CFunahashi T, Tanaka Set al.Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab2001;86:1930–5.
4.
4. Kumada MKihara S, Sumitsuji Set al.for Osaka CAD Study Group. Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol2003;23(1):85–9.
5.
5. Bacha FSaad R, Gungor N, Arslanian AS.Adiponectin in youth: relationship to visceral adiposity, insulin sensitivity, and beta-cell function. Diabetes Care2004;27:547–52.
6.
6. Wang YLam KS, Xu JYet al.Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem2005;280:18341–7.
7.
7. Yudkin JSKumari M, Humpries SE, Mohamed-Ali V.Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?Atherosclerosis1999;148:209–14.
9. Pearson TAMensah GA, Alexander RWet al.Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation2003;107:499–511.
10.
10. Verma SYeh TE.C-reactive protein and atherothrombosis – beyond a biomarker: an actual partaker of lesion formation. Am J Physiol Regul Integr Comp Physiol2003;285:R1253–R1256.
11.
11. Laaksonen DENiskanen L, Nyyssönen Ket al.C-reactive protein and development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia2004;47:1403–10.
12.
12. Gabay CKushner IAcute-phase proteins and other systemic responses to inflammation. N Engl J Med1999;340:448–54.
13.
13. Salmenniemi URuotsalainen E, Pihlajamäki Jet al.Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation2004;110:3842–8.
14.
14. Patti GD'Ambrosio A, Dobrina Aet al.Interleukin-1 receptor antagonist: a sensitive marker of instability in patients with coronary artery disease. J Thromb Thrombolysis2002;14:139–43.
15.
15. Pietrobelli AFaith MS, Allison DB, Gallagher D, Chiumello G, Heymsfield BS.Body mass index as a measure of adiposity among children and adolescents: a validation study. J Pediatr1998;132:204–10.
16.
16. Bellizzi MCDietz HW.Workshop on childhood obesity: summary of the discussion. Am J Clin Nutr1999;70:173S–175S.
17.
17. Warren MSchreiner PJ, Terry GJ.The relation between visceral fat measurement and torso level – is one level better than another? The Atherosclerosis Risk in Communities Study, 1990-1992. Am J Epidemiol2006;163:352–8.
18.
18. Westerbacka JCornér A, Tiikkainen Met al.Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia2004;47:1360–9.
19.
19. Thorand BBaumert J, Döring Aet al.Sex differences in the relation of body composition to markers of inflammation. Atherosclerosis2006;184:216–24.
20.
20. Maedler KSergeev P, Ris Fet al.Glucose-induced beta-cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest2002;110:851–60.
21.
21. Meier CABobbioni E, Gabay C, Assimacopoulos-Jeannet F, Golay A, Dayer JM.IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin?J Clin Endocrinol Metab2002;87:1184–8.
22.
22. Juge-Aubry CE, Somm E, Giusti Vet al.Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes2003;52:1104–10.
23.
23. Ruotsalainen ESalmenniemi U, Vauhkonen Iet al.Changes in inflammatory cytokines are related to impaired glucose tolerance in offspring of type 2 diabetic subjects. Diabetes Care2006;29:2714–20.
24.
24. Arend WPGabay CPhysiologic role of interleukin-1 receptor antagonist. Arthritis Res2000;2:245–8.
25.
25. Larsen CMFaulenbach M, Vaag Aet al.Interleukin-1 receptor antagonist in type 2 diabetes mellitus. N Engl J Med2007;356:1517–26.
27. Weyer CFunahashi T, Tanaka Set al.Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab2001;86:1930–5.
28.
28. Pischon TGirman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm BE.Plasma adiponectin levels and risk of myocardial infarction in men. JAMA2004;291:1730–7.
29.
29. Narayan KMVBoyle J, Thompson TJ, Gregg EW, Williamson DF.Effect of BMI on lifetime risk for diabetes in the US. Diabetes Care2007;30:1562–6.
30.
30. Matsubara MNamioka K, Katayose S.Decreased plasma adiponectin concentrations in women with low-grade C-reactive protein elevation. Eur J Endocrinol2003;148:657–62.
